PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting (NYSE:LLY)

INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced final results of the Phase III PROCLAIM trial that will also be discussed in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. PROCLAIM was a randomized, Phase III superiority study of patients with locally-advanced, nonsquamous non-small cell lung cancer (NSCLC), which evaluated Lilly's ALIMTA^® (pemetrexed for injection), in combination with cisplatin with concurrent radiation followed by maintenance ALIMTA in comparison with etoposide and cisplatin plus concurrent radiation, followed by consolidation chemotherapy of the oncologist's choice.

PROCLAIM was the largest study to evaluate the effect of pemetrexed/platinum plus radiation in this setting. Lilly announced in 2012 that the study enrollment was halted because an Independent Data Monitoring Committee projected that the experimental arm of the study would not meet its primary endpoint of superior overall survival. As no new safety issues were identified, all patients who received treatment with the pemetrexed regimen were allowed to continue their assigned therapy at the discretion of the investigator and were followed for survival with the final results now at ASCO.

PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting (NYSE:LLY)